Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion dollar a year blockbuster drugs and jealousy-inspiring margins, Gilead Sciences sales have soared thanks to new hepatitis C treatments that cure more people, faster, with fewer side effects.